nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—ABCB1—ovarian cancer	0.215	1	CbGaD
Risperidone—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0362	0.0991	CbGbCtD
Risperidone—CYP3A7—Paclitaxel—ovarian cancer	0.0362	0.0991	CbGbCtD
Risperidone—ABCB1—Topotecan—ovarian cancer	0.0357	0.0977	CbGbCtD
Risperidone—CYP3A5—Paclitaxel—ovarian cancer	0.0271	0.0743	CbGbCtD
Risperidone—CYP3A7—Docetaxel—ovarian cancer	0.0262	0.0716	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0262	0.0716	CbGbCtD
Risperidone—ABCB1—Vinorelbine—ovarian cancer	0.0251	0.0688	CbGbCtD
Risperidone—CYP2D6—Vinorelbine—ovarian cancer	0.0237	0.0649	CbGbCtD
Risperidone—CYP3A4—Topotecan—ovarian cancer	0.0214	0.0585	CbGbCtD
Risperidone—CYP3A5—Docetaxel—ovarian cancer	0.0196	0.0537	CbGbCtD
Risperidone—ABCB1—Paclitaxel—ovarian cancer	0.0177	0.0484	CbGbCtD
Risperidone—CYP3A4—Vinorelbine—ovarian cancer	0.0151	0.0412	CbGbCtD
Risperidone—ABCB1—Docetaxel—ovarian cancer	0.0128	0.035	CbGbCtD
Risperidone—CYP3A4—Paclitaxel—ovarian cancer	0.0106	0.029	CbGbCtD
Risperidone—ABCB1—Doxorubicin—ovarian cancer	0.00952	0.0261	CbGbCtD
Risperidone—CYP2D6—Doxorubicin—ovarian cancer	0.00897	0.0246	CbGbCtD
Risperidone—CYP3A4—Docetaxel—ovarian cancer	0.00765	0.021	CbGbCtD
Risperidone—HTR7—vein—ovarian cancer	0.00588	0.072	CbGeAlD
Risperidone—H1F0—oviduct—ovarian cancer	0.00586	0.0718	CbGeAlD
Risperidone—CYP3A4—Doxorubicin—ovarian cancer	0.0057	0.0156	CbGbCtD
Risperidone—HTR2A—vein—ovarian cancer	0.00367	0.0449	CbGeAlD
Risperidone—H1F0—myometrium—ovarian cancer	0.00188	0.023	CbGeAlD
Risperidone—H1F0—embryo—ovarian cancer	0.0018	0.0221	CbGeAlD
Risperidone—DRD4—testis—ovarian cancer	0.00173	0.0212	CbGeAlD
Risperidone—H1F0—uterine cervix—ovarian cancer	0.00146	0.0179	CbGeAlD
Risperidone—H1F0—decidua—ovarian cancer	0.00139	0.017	CbGeAlD
Risperidone—HTR2B—myometrium—ovarian cancer	0.00135	0.0166	CbGeAlD
Risperidone—H1F0—endometrium—ovarian cancer	0.00132	0.0162	CbGeAlD
Risperidone—H1F0—gonad—ovarian cancer	0.00122	0.015	CbGeAlD
Risperidone—H1F0—uterus—ovarian cancer	0.00122	0.0149	CbGeAlD
Risperidone—H1F0—female reproductive system—ovarian cancer	0.00109	0.0134	CbGeAlD
Risperidone—KCNH2—myometrium—ovarian cancer	0.00108	0.0132	CbGeAlD
Risperidone—ADRA2C—myometrium—ovarian cancer	0.00106	0.013	CbGeAlD
Risperidone—HTR2B—uterine cervix—ovarian cancer	0.00105	0.0129	CbGeAlD
Risperidone—H1F0—bone marrow—ovarian cancer	0.00103	0.0126	CbGeAlD
Risperidone—HTR2B—decidua—ovarian cancer	0.001	0.0123	CbGeAlD
Risperidone—H1F0—female gonad—ovarian cancer	0.000995	0.0122	CbGeAlD
Risperidone—H1F0—vagina—ovarian cancer	0.000989	0.0121	CbGeAlD
Risperidone—HTR2B—endometrium—ovarian cancer	0.000951	0.0117	CbGeAlD
Risperidone—HTR7—epithelium—ovarian cancer	0.000908	0.0111	CbGeAlD
Risperidone—H1F0—testis—ovarian cancer	0.000883	0.0108	CbGeAlD
Risperidone—HTR2B—uterus—ovarian cancer	0.000877	0.0107	CbGeAlD
Risperidone—ADRA1A—epithelium—ovarian cancer	0.000876	0.0107	CbGeAlD
Risperidone—HTR1B—female reproductive system—ovarian cancer	0.000875	0.0107	CbGeAlD
Risperidone—HRH1—myometrium—ovarian cancer	0.000864	0.0106	CbGeAlD
Risperidone—ADRA2A—myometrium—ovarian cancer	0.000849	0.0104	CbGeAlD
Risperidone—HTR1D—female reproductive system—ovarian cancer	0.000847	0.0104	CbGeAlD
Risperidone—KCNH2—uterine cervix—ovarian cancer	0.000839	0.0103	CbGeAlD
Risperidone—HTR2C—female reproductive system—ovarian cancer	0.000839	0.0103	CbGeAlD
Risperidone—ADRA2C—uterine cervix—ovarian cancer	0.000828	0.0101	CbGeAlD
Risperidone—ADRA2C—decidua—ovarian cancer	0.000789	0.00966	CbGeAlD
Risperidone—HTR2B—female reproductive system—ovarian cancer	0.000788	0.00965	CbGeAlD
Risperidone—KCNH2—endometrium—ovarian cancer	0.000759	0.00929	CbGeAlD
Risperidone—HTR7—gonad—ovarian cancer	0.000756	0.00925	CbGeAlD
Risperidone—ADRA2C—endometrium—ovarian cancer	0.000749	0.00917	CbGeAlD
Risperidone—HTR2B—vagina—ovarian cancer	0.000713	0.00873	CbGeAlD
Risperidone—KCNH2—uterus—ovarian cancer	0.000699	0.00856	CbGeAlD
Risperidone—HTR2A—embryo—ovarian cancer	0.000694	0.0085	CbGeAlD
Risperidone—CYP3A5—uterine cervix—ovarian cancer	0.000693	0.00849	CbGeAlD
Risperidone—ADRA2C—uterus—ovarian cancer	0.00069	0.00845	CbGeAlD
Risperidone—HRH1—epithelium—ovarian cancer	0.000678	0.00831	CbGeAlD
Risperidone—HTR7—female reproductive system—ovarian cancer	0.000675	0.00826	CbGeAlD
Risperidone—HRH1—uterine cervix—ovarian cancer	0.000673	0.00824	CbGeAlD
Risperidone—ADRA2A—uterine cervix—ovarian cancer	0.000661	0.00809	CbGeAlD
Risperidone—HRH1—decidua—ovarian cancer	0.000641	0.00785	CbGeAlD
Risperidone—H1F0—lymph node—ovarian cancer	0.00064	0.00784	CbGeAlD
Risperidone—ADRA2A—decidua—ovarian cancer	0.000629	0.00771	CbGeAlD
Risperidone—KCNH2—female reproductive system—ovarian cancer	0.000629	0.0077	CbGeAlD
Risperidone—HRH1—endometrium—ovarian cancer	0.000608	0.00745	CbGeAlD
Risperidone—ADRA2A—endometrium—ovarian cancer	0.000597	0.00732	CbGeAlD
Risperidone—KCNH2—bone marrow—ovarian cancer	0.000594	0.00727	CbGeAlD
Risperidone—KCNH2—female gonad—ovarian cancer	0.000572	0.00701	CbGeAlD
Risperidone—KCNH2—vagina—ovarian cancer	0.000569	0.00696	CbGeAlD
Risperidone—HTR2A—epithelium—ovarian cancer	0.000567	0.00694	CbGeAlD
Risperidone—ADRA2C—female gonad—ovarian cancer	0.000564	0.00691	CbGeAlD
Risperidone—ADRA2C—vagina—ovarian cancer	0.000561	0.00687	CbGeAlD
Risperidone—ADRA2A—gonad—ovarian cancer	0.000554	0.00679	CbGeAlD
Risperidone—ADRA2A—uterus—ovarian cancer	0.000551	0.00674	CbGeAlD
Risperidone—HTR7—testis—ovarian cancer	0.000545	0.00667	CbGeAlD
Risperidone—DRD2—testis—ovarian cancer	0.000515	0.00631	CbGeAlD
Risperidone—KCNH2—testis—ovarian cancer	0.000507	0.00621	CbGeAlD
Risperidone—HRH1—female reproductive system—ovarian cancer	0.000504	0.00617	CbGeAlD
Risperidone—ADRA2C—testis—ovarian cancer	0.000501	0.00613	CbGeAlD
Risperidone—ADRA2A—female reproductive system—ovarian cancer	0.000495	0.00606	CbGeAlD
Risperidone—ABCB1—myometrium—ovarian cancer	0.000473	0.00579	CbGeAlD
Risperidone—CYP3A5—female gonad—ovarian cancer	0.000472	0.00579	CbGeAlD
Risperidone—HTR2A—gonad—ovarian cancer	0.000471	0.00577	CbGeAlD
Risperidone—CYP3A5—vagina—ovarian cancer	0.00047	0.00575	CbGeAlD
Risperidone—HTR2B—lymph node—ovarian cancer	0.000461	0.00565	CbGeAlD
Risperidone—HRH1—female gonad—ovarian cancer	0.000459	0.00562	CbGeAlD
Risperidone—HRH1—vagina—ovarian cancer	0.000456	0.00558	CbGeAlD
Risperidone—ABCB1—embryo—ovarian cancer	0.000455	0.00557	CbGeAlD
Risperidone—ADRA2A—female gonad—ovarian cancer	0.00045	0.00552	CbGeAlD
Risperidone—ADRA2A—vagina—ovarian cancer	0.000448	0.00548	CbGeAlD
Risperidone—HTR2A—female reproductive system—ovarian cancer	0.000421	0.00515	CbGeAlD
Risperidone—HRH1—testis—ovarian cancer	0.000407	0.00498	CbGeAlD
Risperidone—ADRA2A—testis—ovarian cancer	0.000399	0.00489	CbGeAlD
Risperidone—CYP3A4—female reproductive system—ovarian cancer	0.00039	0.00477	CbGeAlD
Risperidone—CYP2D6—female reproductive system—ovarian cancer	0.000383	0.0047	CbGeAlD
Risperidone—HTR2A—vagina—ovarian cancer	0.000381	0.00466	CbGeAlD
Risperidone—ABCB1—epithelium—ovarian cancer	0.000371	0.00455	CbGeAlD
Risperidone—ABCB1—uterine cervix—ovarian cancer	0.000368	0.00451	CbGeAlD
Risperidone—KCNH2—lymph node—ovarian cancer	0.000368	0.0045	CbGeAlD
Risperidone—ADRA2C—lymph node—ovarian cancer	0.000363	0.00444	CbGeAlD
Risperidone—ABCB1—decidua—ovarian cancer	0.000351	0.00429	CbGeAlD
Risperidone—CYP2D6—female gonad—ovarian cancer	0.000349	0.00427	CbGeAlD
Risperidone—HTR2A—testis—ovarian cancer	0.00034	0.00416	CbGeAlD
Risperidone—ABCB1—endometrium—ovarian cancer	0.000333	0.00408	CbGeAlD
Risperidone—CYP2D6—testis—ovarian cancer	0.000309	0.00379	CbGeAlD
Risperidone—ABCB1—gonad—ovarian cancer	0.000309	0.00378	CbGeAlD
Risperidone—ABCB1—uterus—ovarian cancer	0.000307	0.00376	CbGeAlD
Risperidone—HRH1—lymph node—ovarian cancer	0.000295	0.00361	CbGeAlD
Risperidone—ADRA2A—lymph node—ovarian cancer	0.00029	0.00355	CbGeAlD
Risperidone—ABCB1—female reproductive system—ovarian cancer	0.000276	0.00338	CbGeAlD
Risperidone—ABCB1—bone marrow—ovarian cancer	0.00026	0.00319	CbGeAlD
Risperidone—ABCB1—female gonad—ovarian cancer	0.000251	0.00307	CbGeAlD
Risperidone—ABCB1—vagina—ovarian cancer	0.000249	0.00305	CbGeAlD
Risperidone—ABCB1—testis—ovarian cancer	0.000223	0.00273	CbGeAlD
Risperidone—ABCB1—lymph node—ovarian cancer	0.000161	0.00198	CbGeAlD
Risperidone—Epistaxis—Epirubicin—ovarian cancer	9.33e-05	0.000301	CcSEcCtD
Risperidone—Infection—Docetaxel—ovarian cancer	9.29e-05	0.0003	CcSEcCtD
Risperidone—Weight decreased—Doxorubicin—ovarian cancer	9.29e-05	0.000299	CcSEcCtD
Risperidone—Sinusitis—Epirubicin—ovarian cancer	9.28e-05	0.000299	CcSEcCtD
Risperidone—Hyperglycaemia—Doxorubicin—ovarian cancer	9.26e-05	0.000299	CcSEcCtD
Risperidone—Agranulocytosis—Epirubicin—ovarian cancer	9.23e-05	0.000298	CcSEcCtD
Risperidone—Pneumonia—Doxorubicin—ovarian cancer	9.21e-05	0.000297	CcSEcCtD
Risperidone—Shock—Docetaxel—ovarian cancer	9.2e-05	0.000297	CcSEcCtD
Risperidone—Nervous system disorder—Docetaxel—ovarian cancer	9.17e-05	0.000296	CcSEcCtD
Risperidone—Thrombocytopenia—Docetaxel—ovarian cancer	9.16e-05	0.000295	CcSEcCtD
Risperidone—Infestation NOS—Doxorubicin—ovarian cancer	9.15e-05	0.000295	CcSEcCtD
Risperidone—Drowsiness—Doxorubicin—ovarian cancer	9.15e-05	0.000295	CcSEcCtD
Risperidone—Infestation—Doxorubicin—ovarian cancer	9.15e-05	0.000295	CcSEcCtD
Risperidone—Tachycardia—Docetaxel—ovarian cancer	9.13e-05	0.000294	CcSEcCtD
Risperidone—Feeling abnormal—Paclitaxel—ovarian cancer	9.09e-05	0.000293	CcSEcCtD
Risperidone—Skin disorder—Docetaxel—ovarian cancer	9.09e-05	0.000293	CcSEcCtD
Risperidone—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	9.07e-05	0.000293	CcSEcCtD
Risperidone—Bradycardia—Epirubicin—ovarian cancer	9.04e-05	0.000291	CcSEcCtD
Risperidone—Gastrointestinal pain—Paclitaxel—ovarian cancer	9.02e-05	0.000291	CcSEcCtD
Risperidone—Renal failure—Doxorubicin—ovarian cancer	9e-05	0.00029	CcSEcCtD
Risperidone—Neuropathy peripheral—Doxorubicin—ovarian cancer	8.97e-05	0.000289	CcSEcCtD
Risperidone—Haemoglobin—Epirubicin—ovarian cancer	8.93e-05	0.000288	CcSEcCtD
Risperidone—Jaundice—Doxorubicin—ovarian cancer	8.92e-05	0.000288	CcSEcCtD
Risperidone—Stomatitis—Doxorubicin—ovarian cancer	8.92e-05	0.000288	CcSEcCtD
Risperidone—Anorexia—Docetaxel—ovarian cancer	8.92e-05	0.000287	CcSEcCtD
Risperidone—Rhinitis—Epirubicin—ovarian cancer	8.9e-05	0.000287	CcSEcCtD
Risperidone—Urinary tract infection—Doxorubicin—ovarian cancer	8.9e-05	0.000287	CcSEcCtD
Risperidone—Conjunctivitis—Doxorubicin—ovarian cancer	8.9e-05	0.000287	CcSEcCtD
Risperidone—Haemorrhage—Epirubicin—ovarian cancer	8.88e-05	0.000286	CcSEcCtD
Risperidone—Hepatitis—Epirubicin—ovarian cancer	8.88e-05	0.000286	CcSEcCtD
Risperidone—Hypoaesthesia—Epirubicin—ovarian cancer	8.84e-05	0.000285	CcSEcCtD
Risperidone—Pharyngitis—Epirubicin—ovarian cancer	8.81e-05	0.000284	CcSEcCtD
Risperidone—Sweating—Doxorubicin—ovarian cancer	8.78e-05	0.000283	CcSEcCtD
Risperidone—Urinary tract disorder—Epirubicin—ovarian cancer	8.77e-05	0.000283	CcSEcCtD
Risperidone—Urticaria—Paclitaxel—ovarian cancer	8.77e-05	0.000283	CcSEcCtD
Risperidone—Oedema peripheral—Epirubicin—ovarian cancer	8.75e-05	0.000282	CcSEcCtD
Risperidone—Hypotension—Docetaxel—ovarian cancer	8.74e-05	0.000282	CcSEcCtD
Risperidone—Haematuria—Doxorubicin—ovarian cancer	8.73e-05	0.000281	CcSEcCtD
Risperidone—Connective tissue disorder—Epirubicin—ovarian cancer	8.73e-05	0.000281	CcSEcCtD
Risperidone—Abdominal pain—Paclitaxel—ovarian cancer	8.72e-05	0.000281	CcSEcCtD
Risperidone—Body temperature increased—Paclitaxel—ovarian cancer	8.72e-05	0.000281	CcSEcCtD
Risperidone—Urethral disorder—Epirubicin—ovarian cancer	8.71e-05	0.000281	CcSEcCtD
Risperidone—Hepatobiliary disease—Doxorubicin—ovarian cancer	8.66e-05	0.000279	CcSEcCtD
Risperidone—Epistaxis—Doxorubicin—ovarian cancer	8.63e-05	0.000278	CcSEcCtD
Risperidone—Sinusitis—Doxorubicin—ovarian cancer	8.59e-05	0.000277	CcSEcCtD
Risperidone—Visual impairment—Epirubicin—ovarian cancer	8.56e-05	0.000276	CcSEcCtD
Risperidone—Agranulocytosis—Doxorubicin—ovarian cancer	8.54e-05	0.000275	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	8.52e-05	0.000275	CcSEcCtD
Risperidone—Insomnia—Docetaxel—ovarian cancer	8.46e-05	0.000273	CcSEcCtD
Risperidone—Paraesthesia—Docetaxel—ovarian cancer	8.4e-05	0.000271	CcSEcCtD
Risperidone—Erythema multiforme—Epirubicin—ovarian cancer	8.4e-05	0.000271	CcSEcCtD
Risperidone—Bradycardia—Doxorubicin—ovarian cancer	8.37e-05	0.00027	CcSEcCtD
Risperidone—Dyspnoea—Docetaxel—ovarian cancer	8.34e-05	0.000269	CcSEcCtD
Risperidone—Somnolence—Docetaxel—ovarian cancer	8.32e-05	0.000268	CcSEcCtD
Risperidone—Eye disorder—Epirubicin—ovarian cancer	8.3e-05	0.000268	CcSEcCtD
Risperidone—Tinnitus—Epirubicin—ovarian cancer	8.28e-05	0.000267	CcSEcCtD
Risperidone—Haemoglobin—Doxorubicin—ovarian cancer	8.26e-05	0.000266	CcSEcCtD
Risperidone—Flushing—Epirubicin—ovarian cancer	8.24e-05	0.000266	CcSEcCtD
Risperidone—Cardiac disorder—Epirubicin—ovarian cancer	8.24e-05	0.000266	CcSEcCtD
Risperidone—Rhinitis—Doxorubicin—ovarian cancer	8.24e-05	0.000266	CcSEcCtD
Risperidone—Dyspepsia—Docetaxel—ovarian cancer	8.23e-05	0.000265	CcSEcCtD
Risperidone—Haemorrhage—Doxorubicin—ovarian cancer	8.22e-05	0.000265	CcSEcCtD
Risperidone—Hepatitis—Doxorubicin—ovarian cancer	8.22e-05	0.000265	CcSEcCtD
Risperidone—Hypoaesthesia—Doxorubicin—ovarian cancer	8.18e-05	0.000264	CcSEcCtD
Risperidone—Pharyngitis—Doxorubicin—ovarian cancer	8.16e-05	0.000263	CcSEcCtD
Risperidone—Decreased appetite—Docetaxel—ovarian cancer	8.13e-05	0.000262	CcSEcCtD
Risperidone—Hypersensitivity—Paclitaxel—ovarian cancer	8.13e-05	0.000262	CcSEcCtD
Risperidone—Urinary tract disorder—Doxorubicin—ovarian cancer	8.11e-05	0.000262	CcSEcCtD
Risperidone—Oedema peripheral—Doxorubicin—ovarian cancer	8.09e-05	0.000261	CcSEcCtD
Risperidone—Gastrointestinal disorder—Docetaxel—ovarian cancer	8.08e-05	0.00026	CcSEcCtD
Risperidone—Connective tissue disorder—Doxorubicin—ovarian cancer	8.07e-05	0.00026	CcSEcCtD
Risperidone—Fatigue—Docetaxel—ovarian cancer	8.06e-05	0.00026	CcSEcCtD
Risperidone—Angiopathy—Epirubicin—ovarian cancer	8.06e-05	0.00026	CcSEcCtD
Risperidone—Urethral disorder—Doxorubicin—ovarian cancer	8.05e-05	0.00026	CcSEcCtD
Risperidone—Immune system disorder—Epirubicin—ovarian cancer	8.02e-05	0.000259	CcSEcCtD
Risperidone—Mediastinal disorder—Epirubicin—ovarian cancer	8e-05	0.000258	CcSEcCtD
Risperidone—Pain—Docetaxel—ovarian cancer	8e-05	0.000258	CcSEcCtD
Risperidone—Constipation—Docetaxel—ovarian cancer	8e-05	0.000258	CcSEcCtD
Risperidone—Chills—Epirubicin—ovarian cancer	7.97e-05	0.000257	CcSEcCtD
Risperidone—Arrhythmia—Epirubicin—ovarian cancer	7.93e-05	0.000256	CcSEcCtD
Risperidone—Visual impairment—Doxorubicin—ovarian cancer	7.92e-05	0.000255	CcSEcCtD
Risperidone—Asthenia—Paclitaxel—ovarian cancer	7.92e-05	0.000255	CcSEcCtD
Risperidone—Alopecia—Epirubicin—ovarian cancer	7.85e-05	0.000253	CcSEcCtD
Risperidone—Pruritus—Paclitaxel—ovarian cancer	7.81e-05	0.000252	CcSEcCtD
Risperidone—Mental disorder—Epirubicin—ovarian cancer	7.78e-05	0.000251	CcSEcCtD
Risperidone—Erythema multiforme—Doxorubicin—ovarian cancer	7.77e-05	0.00025	CcSEcCtD
Risperidone—Erythema—Epirubicin—ovarian cancer	7.73e-05	0.000249	CcSEcCtD
Risperidone—Malnutrition—Epirubicin—ovarian cancer	7.73e-05	0.000249	CcSEcCtD
Risperidone—Feeling abnormal—Docetaxel—ovarian cancer	7.71e-05	0.000248	CcSEcCtD
Risperidone—Eye disorder—Doxorubicin—ovarian cancer	7.68e-05	0.000248	CcSEcCtD
Risperidone—Tinnitus—Doxorubicin—ovarian cancer	7.66e-05	0.000247	CcSEcCtD
Risperidone—Gastrointestinal pain—Docetaxel—ovarian cancer	7.65e-05	0.000247	CcSEcCtD
Risperidone—Flushing—Doxorubicin—ovarian cancer	7.63e-05	0.000246	CcSEcCtD
Risperidone—Cardiac disorder—Doxorubicin—ovarian cancer	7.63e-05	0.000246	CcSEcCtD
Risperidone—Flatulence—Epirubicin—ovarian cancer	7.62e-05	0.000246	CcSEcCtD
Risperidone—Tension—Epirubicin—ovarian cancer	7.59e-05	0.000245	CcSEcCtD
Risperidone—Dysgeusia—Epirubicin—ovarian cancer	7.57e-05	0.000244	CcSEcCtD
Risperidone—Diarrhoea—Paclitaxel—ovarian cancer	7.55e-05	0.000243	CcSEcCtD
Risperidone—Nervousness—Epirubicin—ovarian cancer	7.51e-05	0.000242	CcSEcCtD
Risperidone—Back pain—Epirubicin—ovarian cancer	7.48e-05	0.000241	CcSEcCtD
Risperidone—Angiopathy—Doxorubicin—ovarian cancer	7.46e-05	0.00024	CcSEcCtD
Risperidone—Muscle spasms—Epirubicin—ovarian cancer	7.43e-05	0.00024	CcSEcCtD
Risperidone—Immune system disorder—Doxorubicin—ovarian cancer	7.42e-05	0.000239	CcSEcCtD
Risperidone—Mediastinal disorder—Doxorubicin—ovarian cancer	7.41e-05	0.000239	CcSEcCtD
Risperidone—Abdominal pain—Docetaxel—ovarian cancer	7.39e-05	0.000238	CcSEcCtD
Risperidone—Body temperature increased—Docetaxel—ovarian cancer	7.39e-05	0.000238	CcSEcCtD
Risperidone—Chills—Doxorubicin—ovarian cancer	7.37e-05	0.000238	CcSEcCtD
Risperidone—Arrhythmia—Doxorubicin—ovarian cancer	7.34e-05	0.000237	CcSEcCtD
Risperidone—Dizziness—Paclitaxel—ovarian cancer	7.3e-05	0.000235	CcSEcCtD
Risperidone—Vision blurred—Epirubicin—ovarian cancer	7.29e-05	0.000235	CcSEcCtD
Risperidone—Alopecia—Doxorubicin—ovarian cancer	7.26e-05	0.000234	CcSEcCtD
Risperidone—Mental disorder—Doxorubicin—ovarian cancer	7.2e-05	0.000232	CcSEcCtD
Risperidone—Ill-defined disorder—Epirubicin—ovarian cancer	7.17e-05	0.000231	CcSEcCtD
Risperidone—Erythema—Doxorubicin—ovarian cancer	7.15e-05	0.000231	CcSEcCtD
Risperidone—Malnutrition—Doxorubicin—ovarian cancer	7.15e-05	0.000231	CcSEcCtD
Risperidone—Anaemia—Epirubicin—ovarian cancer	7.15e-05	0.00023	CcSEcCtD
Risperidone—Agitation—Epirubicin—ovarian cancer	7.1e-05	0.000229	CcSEcCtD
Risperidone—Flatulence—Doxorubicin—ovarian cancer	7.05e-05	0.000227	CcSEcCtD
Risperidone—Tension—Doxorubicin—ovarian cancer	7.02e-05	0.000226	CcSEcCtD
Risperidone—Vomiting—Paclitaxel—ovarian cancer	7.02e-05	0.000226	CcSEcCtD
Risperidone—Dysgeusia—Doxorubicin—ovarian cancer	7e-05	0.000226	CcSEcCtD
Risperidone—Malaise—Epirubicin—ovarian cancer	6.97e-05	0.000225	CcSEcCtD
Risperidone—Rash—Paclitaxel—ovarian cancer	6.96e-05	0.000224	CcSEcCtD
Risperidone—Dermatitis—Paclitaxel—ovarian cancer	6.95e-05	0.000224	CcSEcCtD
Risperidone—Nervousness—Doxorubicin—ovarian cancer	6.95e-05	0.000224	CcSEcCtD
Risperidone—Vertigo—Epirubicin—ovarian cancer	6.95e-05	0.000224	CcSEcCtD
Risperidone—Syncope—Epirubicin—ovarian cancer	6.93e-05	0.000223	CcSEcCtD
Risperidone—Leukopenia—Epirubicin—ovarian cancer	6.92e-05	0.000223	CcSEcCtD
Risperidone—Back pain—Doxorubicin—ovarian cancer	6.92e-05	0.000223	CcSEcCtD
Risperidone—Headache—Paclitaxel—ovarian cancer	6.91e-05	0.000223	CcSEcCtD
Risperidone—Hypersensitivity—Docetaxel—ovarian cancer	6.89e-05	0.000222	CcSEcCtD
Risperidone—Muscle spasms—Doxorubicin—ovarian cancer	6.88e-05	0.000222	CcSEcCtD
Risperidone—Palpitations—Epirubicin—ovarian cancer	6.83e-05	0.00022	CcSEcCtD
Risperidone—Loss of consciousness—Epirubicin—ovarian cancer	6.79e-05	0.000219	CcSEcCtD
Risperidone—Cough—Epirubicin—ovarian cancer	6.75e-05	0.000217	CcSEcCtD
Risperidone—Vision blurred—Doxorubicin—ovarian cancer	6.74e-05	0.000217	CcSEcCtD
Risperidone—Asthenia—Docetaxel—ovarian cancer	6.71e-05	0.000216	CcSEcCtD
Risperidone—Convulsion—Epirubicin—ovarian cancer	6.7e-05	0.000216	CcSEcCtD
Risperidone—Hypertension—Epirubicin—ovarian cancer	6.67e-05	0.000215	CcSEcCtD
Risperidone—Ill-defined disorder—Doxorubicin—ovarian cancer	6.64e-05	0.000214	CcSEcCtD
Risperidone—Pruritus—Docetaxel—ovarian cancer	6.62e-05	0.000213	CcSEcCtD
Risperidone—Anaemia—Doxorubicin—ovarian cancer	6.61e-05	0.000213	CcSEcCtD
Risperidone—Arthralgia—Epirubicin—ovarian cancer	6.58e-05	0.000212	CcSEcCtD
Risperidone—Myalgia—Epirubicin—ovarian cancer	6.58e-05	0.000212	CcSEcCtD
Risperidone—Chest pain—Epirubicin—ovarian cancer	6.58e-05	0.000212	CcSEcCtD
Risperidone—Agitation—Doxorubicin—ovarian cancer	6.57e-05	0.000212	CcSEcCtD
Risperidone—Anxiety—Epirubicin—ovarian cancer	6.56e-05	0.000211	CcSEcCtD
Risperidone—Nausea—Paclitaxel—ovarian cancer	6.56e-05	0.000211	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	6.54e-05	0.000211	CcSEcCtD
Risperidone—Discomfort—Epirubicin—ovarian cancer	6.5e-05	0.00021	CcSEcCtD
Risperidone—Malaise—Doxorubicin—ovarian cancer	6.45e-05	0.000208	CcSEcCtD
Risperidone—Dry mouth—Epirubicin—ovarian cancer	6.44e-05	0.000208	CcSEcCtD
Risperidone—Vertigo—Doxorubicin—ovarian cancer	6.43e-05	0.000207	CcSEcCtD
Risperidone—Syncope—Doxorubicin—ovarian cancer	6.41e-05	0.000207	CcSEcCtD
Risperidone—Leukopenia—Doxorubicin—ovarian cancer	6.4e-05	0.000206	CcSEcCtD
Risperidone—Diarrhoea—Docetaxel—ovarian cancer	6.4e-05	0.000206	CcSEcCtD
Risperidone—Confusional state—Epirubicin—ovarian cancer	6.36e-05	0.000205	CcSEcCtD
Risperidone—Palpitations—Doxorubicin—ovarian cancer	6.32e-05	0.000204	CcSEcCtD
Risperidone—Oedema—Epirubicin—ovarian cancer	6.31e-05	0.000203	CcSEcCtD
Risperidone—Anaphylactic shock—Epirubicin—ovarian cancer	6.31e-05	0.000203	CcSEcCtD
Risperidone—Loss of consciousness—Doxorubicin—ovarian cancer	6.29e-05	0.000203	CcSEcCtD
Risperidone—Infection—Epirubicin—ovarian cancer	6.27e-05	0.000202	CcSEcCtD
Risperidone—Cough—Doxorubicin—ovarian cancer	6.24e-05	0.000201	CcSEcCtD
Risperidone—Shock—Epirubicin—ovarian cancer	6.21e-05	0.0002	CcSEcCtD
Risperidone—Convulsion—Doxorubicin—ovarian cancer	6.2e-05	0.0002	CcSEcCtD
Risperidone—Nervous system disorder—Epirubicin—ovarian cancer	6.19e-05	0.000199	CcSEcCtD
Risperidone—Dizziness—Docetaxel—ovarian cancer	6.19e-05	0.000199	CcSEcCtD
Risperidone—Thrombocytopenia—Epirubicin—ovarian cancer	6.18e-05	0.000199	CcSEcCtD
Risperidone—Hypertension—Doxorubicin—ovarian cancer	6.18e-05	0.000199	CcSEcCtD
Risperidone—Tachycardia—Epirubicin—ovarian cancer	6.16e-05	0.000199	CcSEcCtD
Risperidone—Skin disorder—Epirubicin—ovarian cancer	6.13e-05	0.000198	CcSEcCtD
Risperidone—Hyperhidrosis—Epirubicin—ovarian cancer	6.1e-05	0.000197	CcSEcCtD
Risperidone—Myalgia—Doxorubicin—ovarian cancer	6.09e-05	0.000196	CcSEcCtD
Risperidone—Arthralgia—Doxorubicin—ovarian cancer	6.09e-05	0.000196	CcSEcCtD
Risperidone—Chest pain—Doxorubicin—ovarian cancer	6.09e-05	0.000196	CcSEcCtD
Risperidone—Anxiety—Doxorubicin—ovarian cancer	6.07e-05	0.000196	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.05e-05	0.000195	CcSEcCtD
Risperidone—Discomfort—Doxorubicin—ovarian cancer	6.02e-05	0.000194	CcSEcCtD
Risperidone—Anorexia—Epirubicin—ovarian cancer	6.01e-05	0.000194	CcSEcCtD
Risperidone—Dry mouth—Doxorubicin—ovarian cancer	5.96e-05	0.000192	CcSEcCtD
Risperidone—Vomiting—Docetaxel—ovarian cancer	5.95e-05	0.000192	CcSEcCtD
Risperidone—Rash—Docetaxel—ovarian cancer	5.9e-05	0.00019	CcSEcCtD
Risperidone—Hypotension—Epirubicin—ovarian cancer	5.9e-05	0.00019	CcSEcCtD
Risperidone—Dermatitis—Docetaxel—ovarian cancer	5.89e-05	0.00019	CcSEcCtD
Risperidone—Confusional state—Doxorubicin—ovarian cancer	5.89e-05	0.00019	CcSEcCtD
Risperidone—Headache—Docetaxel—ovarian cancer	5.86e-05	0.000189	CcSEcCtD
Risperidone—Anaphylactic shock—Doxorubicin—ovarian cancer	5.84e-05	0.000188	CcSEcCtD
Risperidone—Oedema—Doxorubicin—ovarian cancer	5.84e-05	0.000188	CcSEcCtD
Risperidone—Infection—Doxorubicin—ovarian cancer	5.8e-05	0.000187	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.75e-05	0.000185	CcSEcCtD
Risperidone—Shock—Doxorubicin—ovarian cancer	5.74e-05	0.000185	CcSEcCtD
Risperidone—Nervous system disorder—Doxorubicin—ovarian cancer	5.73e-05	0.000185	CcSEcCtD
Risperidone—Thrombocytopenia—Doxorubicin—ovarian cancer	5.72e-05	0.000184	CcSEcCtD
Risperidone—Insomnia—Epirubicin—ovarian cancer	5.71e-05	0.000184	CcSEcCtD
Risperidone—Tachycardia—Doxorubicin—ovarian cancer	5.7e-05	0.000184	CcSEcCtD
Risperidone—Skin disorder—Doxorubicin—ovarian cancer	5.67e-05	0.000183	CcSEcCtD
Risperidone—Paraesthesia—Epirubicin—ovarian cancer	5.67e-05	0.000183	CcSEcCtD
Risperidone—Hyperhidrosis—Doxorubicin—ovarian cancer	5.64e-05	0.000182	CcSEcCtD
Risperidone—Dyspnoea—Epirubicin—ovarian cancer	5.63e-05	0.000181	CcSEcCtD
Risperidone—Somnolence—Epirubicin—ovarian cancer	5.61e-05	0.000181	CcSEcCtD
Risperidone—Anorexia—Doxorubicin—ovarian cancer	5.56e-05	0.000179	CcSEcCtD
Risperidone—Nausea—Docetaxel—ovarian cancer	5.56e-05	0.000179	CcSEcCtD
Risperidone—Dyspepsia—Epirubicin—ovarian cancer	5.55e-05	0.000179	CcSEcCtD
Risperidone—Decreased appetite—Epirubicin—ovarian cancer	5.48e-05	0.000177	CcSEcCtD
Risperidone—Hypotension—Doxorubicin—ovarian cancer	5.46e-05	0.000176	CcSEcCtD
Risperidone—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.45e-05	0.000176	CcSEcCtD
Risperidone—Fatigue—Epirubicin—ovarian cancer	5.44e-05	0.000175	CcSEcCtD
Risperidone—Constipation—Epirubicin—ovarian cancer	5.4e-05	0.000174	CcSEcCtD
Risperidone—Pain—Epirubicin—ovarian cancer	5.4e-05	0.000174	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	5.32e-05	0.000171	CcSEcCtD
Risperidone—Insomnia—Doxorubicin—ovarian cancer	5.28e-05	0.00017	CcSEcCtD
Risperidone—Paraesthesia—Doxorubicin—ovarian cancer	5.24e-05	0.000169	CcSEcCtD
Risperidone—Dyspnoea—Doxorubicin—ovarian cancer	5.2e-05	0.000168	CcSEcCtD
Risperidone—Feeling abnormal—Epirubicin—ovarian cancer	5.2e-05	0.000168	CcSEcCtD
Risperidone—Somnolence—Doxorubicin—ovarian cancer	5.19e-05	0.000167	CcSEcCtD
Risperidone—Gastrointestinal pain—Epirubicin—ovarian cancer	5.16e-05	0.000166	CcSEcCtD
Risperidone—Dyspepsia—Doxorubicin—ovarian cancer	5.14e-05	0.000166	CcSEcCtD
Risperidone—Decreased appetite—Doxorubicin—ovarian cancer	5.07e-05	0.000164	CcSEcCtD
Risperidone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.04e-05	0.000162	CcSEcCtD
Risperidone—Fatigue—Doxorubicin—ovarian cancer	5.03e-05	0.000162	CcSEcCtD
Risperidone—Urticaria—Epirubicin—ovarian cancer	5.01e-05	0.000162	CcSEcCtD
Risperidone—Constipation—Doxorubicin—ovarian cancer	4.99e-05	0.000161	CcSEcCtD
Risperidone—Pain—Doxorubicin—ovarian cancer	4.99e-05	0.000161	CcSEcCtD
Risperidone—Abdominal pain—Epirubicin—ovarian cancer	4.99e-05	0.000161	CcSEcCtD
Risperidone—Body temperature increased—Epirubicin—ovarian cancer	4.99e-05	0.000161	CcSEcCtD
Risperidone—Feeling abnormal—Doxorubicin—ovarian cancer	4.81e-05	0.000155	CcSEcCtD
Risperidone—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.77e-05	0.000154	CcSEcCtD
Risperidone—Hypersensitivity—Epirubicin—ovarian cancer	4.65e-05	0.00015	CcSEcCtD
Risperidone—Urticaria—Doxorubicin—ovarian cancer	4.64e-05	0.00015	CcSEcCtD
Risperidone—Abdominal pain—Doxorubicin—ovarian cancer	4.62e-05	0.000149	CcSEcCtD
Risperidone—Body temperature increased—Doxorubicin—ovarian cancer	4.62e-05	0.000149	CcSEcCtD
Risperidone—Asthenia—Epirubicin—ovarian cancer	4.53e-05	0.000146	CcSEcCtD
Risperidone—Pruritus—Epirubicin—ovarian cancer	4.46e-05	0.000144	CcSEcCtD
Risperidone—Diarrhoea—Epirubicin—ovarian cancer	4.32e-05	0.000139	CcSEcCtD
Risperidone—Hypersensitivity—Doxorubicin—ovarian cancer	4.3e-05	0.000139	CcSEcCtD
Risperidone—Asthenia—Doxorubicin—ovarian cancer	4.19e-05	0.000135	CcSEcCtD
Risperidone—Dizziness—Epirubicin—ovarian cancer	4.17e-05	0.000134	CcSEcCtD
Risperidone—Pruritus—Doxorubicin—ovarian cancer	4.13e-05	0.000133	CcSEcCtD
Risperidone—Vomiting—Epirubicin—ovarian cancer	4.01e-05	0.000129	CcSEcCtD
Risperidone—Diarrhoea—Doxorubicin—ovarian cancer	3.99e-05	0.000129	CcSEcCtD
Risperidone—Rash—Epirubicin—ovarian cancer	3.98e-05	0.000128	CcSEcCtD
Risperidone—Dermatitis—Epirubicin—ovarian cancer	3.97e-05	0.000128	CcSEcCtD
Risperidone—Headache—Epirubicin—ovarian cancer	3.95e-05	0.000127	CcSEcCtD
Risperidone—Dizziness—Doxorubicin—ovarian cancer	3.86e-05	0.000124	CcSEcCtD
Risperidone—Nausea—Epirubicin—ovarian cancer	3.75e-05	0.000121	CcSEcCtD
Risperidone—Vomiting—Doxorubicin—ovarian cancer	3.71e-05	0.00012	CcSEcCtD
Risperidone—Rash—Doxorubicin—ovarian cancer	3.68e-05	0.000119	CcSEcCtD
Risperidone—Dermatitis—Doxorubicin—ovarian cancer	3.68e-05	0.000119	CcSEcCtD
Risperidone—Headache—Doxorubicin—ovarian cancer	3.66e-05	0.000118	CcSEcCtD
Risperidone—Nausea—Doxorubicin—ovarian cancer	3.47e-05	0.000112	CcSEcCtD
Risperidone—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	2.85e-06	0.000103	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	2.85e-06	0.000103	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CASP3—ovarian cancer	2.84e-06	0.000103	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL2—ovarian cancer	2.84e-06	0.000103	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MAPK1—ovarian cancer	2.84e-06	0.000103	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—EGFR—ovarian cancer	2.84e-06	0.000103	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	2.83e-06	0.000103	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—IL6—ovarian cancer	2.83e-06	0.000102	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	2.83e-06	0.000102	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	2.82e-06	0.000102	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	2.82e-06	0.000102	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	2.82e-06	0.000102	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.82e-06	0.000102	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	2.81e-06	0.000102	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	2.81e-06	0.000102	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—TP53—ovarian cancer	2.8e-06	0.000102	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CASP3—ovarian cancer	2.8e-06	0.000101	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	2.8e-06	0.000101	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL2—ovarian cancer	2.8e-06	0.000101	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CASP3—ovarian cancer	2.79e-06	0.000101	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL2—ovarian cancer	2.79e-06	0.000101	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—TP53—ovarian cancer	2.79e-06	0.000101	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—IL6—ovarian cancer	2.78e-06	0.000101	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—IL6—ovarian cancer	2.78e-06	0.000101	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	2.77e-06	0.000101	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCND1—ovarian cancer	2.77e-06	0.0001	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	2.77e-06	0.0001	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	2.77e-06	0.0001	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	2.77e-06	0.0001	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.75e-06	9.97e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	2.75e-06	9.97e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	2.74e-06	9.94e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	2.74e-06	9.94e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL2—ovarian cancer	2.74e-06	9.92e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	2.74e-06	9.92e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—TP53—ovarian cancer	2.73e-06	9.89e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCND1—ovarian cancer	2.72e-06	9.88e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	2.72e-06	9.87e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—STAT3—ovarian cancer	2.72e-06	9.87e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCND1—ovarian cancer	2.72e-06	9.86e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—KRAS—ovarian cancer	2.72e-06	9.86e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—NRAS—ovarian cancer	2.72e-06	9.85e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—STAT3—ovarian cancer	2.71e-06	9.82e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—NRAS—ovarian cancer	2.7e-06	9.8e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	2.7e-06	9.78e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	2.69e-06	9.77e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	2.69e-06	9.76e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MMP9—ovarian cancer	2.69e-06	9.75e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—TP53—ovarian cancer	2.68e-06	9.73e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—KRAS—ovarian cancer	2.68e-06	9.72e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—HRAS—ovarian cancer	2.68e-06	9.72e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PTEN—ovarian cancer	2.67e-06	9.69e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	2.67e-06	9.67e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—HRAS—ovarian cancer	2.66e-06	9.66e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	2.66e-06	9.65e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	2.66e-06	9.65e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	2.65e-06	9.6e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MMP9—ovarian cancer	2.65e-06	9.59e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	2.64e-06	9.58e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	2.64e-06	9.58e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MMP9—ovarian cancer	2.64e-06	9.57e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	2.63e-06	9.55e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PTEN—ovarian cancer	2.63e-06	9.53e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	2.63e-06	9.53e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.63e-06	9.52e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PTEN—ovarian cancer	2.62e-06	9.51e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTEN—ovarian cancer	2.62e-06	9.51e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MYC—ovarian cancer	2.62e-06	9.5e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	2.62e-06	9.49e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—HRAS—ovarian cancer	2.61e-06	9.46e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—AKT1—ovarian cancer	2.61e-06	9.45e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	2.6e-06	9.43e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	2.6e-06	9.42e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	2.59e-06	9.4e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	2.59e-06	9.39e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	2.59e-06	9.38e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	2.59e-06	9.38e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	2.58e-06	9.34e-05	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	2.57e-06	9.32e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—HRAS—ovarian cancer	2.57e-06	9.31e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—IL6—ovarian cancer	2.57e-06	9.3e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	2.57e-06	9.3e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	2.56e-06	9.29e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	2.56e-06	9.29e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—TP53—ovarian cancer	2.56e-06	9.29e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—AKT1—ovarian cancer	2.56e-06	9.28e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—PIK3CA—ovarian cancer	2.56e-06	9.28e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.55e-06	9.26e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—IL6—ovarian cancer	2.55e-06	9.24e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	2.55e-06	9.23e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL2—ovarian cancer	2.54e-06	9.22e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	2.53e-06	9.17e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MYC—ovarian cancer	2.53e-06	9.17e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	2.52e-06	9.12e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MYC—ovarian cancer	2.52e-06	9.12e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	2.51e-06	9.11e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—TYMS—ovarian cancer	2.51e-06	9.09e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	2.5e-06	9.05e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—IL6—ovarian cancer	2.5e-06	9.05e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—PIK3CA—ovarian cancer	2.49e-06	9.01e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	2.48e-06	8.99e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	2.48e-06	8.98e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.48e-06	8.98e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	2.47e-06	8.97e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—EGFR—ovarian cancer	2.47e-06	8.97e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	2.46e-06	8.93e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	2.46e-06	8.93e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—EGFR—ovarian cancer	2.46e-06	8.92e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—IL6—ovarian cancer	2.46e-06	8.91e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	2.45e-06	8.9e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—HRAS—ovarian cancer	2.45e-06	8.88e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MYC—ovarian cancer	2.45e-06	8.88e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	2.42e-06	8.78e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TP53—ovarian cancer	2.42e-06	8.76e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—VEGFA—ovarian cancer	2.41e-06	8.75e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MYC—ovarian cancer	2.41e-06	8.73e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	2.41e-06	8.73e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	2.39e-06	8.68e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	2.39e-06	8.68e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	2.39e-06	8.67e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—STAT3—ovarian cancer	2.39e-06	8.67e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NRAS—ovarian cancer	2.38e-06	8.65e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TP53—ovarian cancer	2.38e-06	8.64e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	2.38e-06	8.61e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—VEGFA—ovarian cancer	2.37e-06	8.59e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—AKT1—ovarian cancer	2.37e-06	8.58e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	2.36e-06	8.55e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	2.36e-06	8.54e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—STAT3—ovarian cancer	2.35e-06	8.53e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—AKT1—ovarian cancer	2.35e-06	8.53e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—STAT3—ovarian cancer	2.35e-06	8.51e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NRAS—ovarian cancer	2.35e-06	8.51e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—IL6—ovarian cancer	2.35e-06	8.5e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NRAS—ovarian cancer	2.34e-06	8.49e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—KRAS—ovarian cancer	2.34e-06	8.47e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	2.33e-06	8.46e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	2.33e-06	8.43e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—KRAS—ovarian cancer	2.33e-06	8.43e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—HRAS—ovarian cancer	2.31e-06	8.38e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	2.3e-06	8.35e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—AKT1—ovarian cancer	2.3e-06	8.35e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	2.3e-06	8.33e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.29e-06	8.3e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MAPK3—ovarian cancer	2.28e-06	8.28e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—HRAS—ovarian cancer	2.28e-06	8.27e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—AKT1—ovarian cancer	2.27e-06	8.22e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	2.26e-06	8.2e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	2.25e-06	8.15e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MAPK3—ovarian cancer	2.24e-06	8.13e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	2.23e-06	8.07e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	2.22e-06	8.07e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MYC—ovarian cancer	2.22e-06	8.05e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—IL6—ovarian cancer	2.21e-06	8.02e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	2.2e-06	7.98e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MYC—ovarian cancer	2.19e-06	7.92e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—IL6—ovarian cancer	2.18e-06	7.91e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MYC—ovarian cancer	2.18e-06	7.91e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MAPK1—ovarian cancer	2.17e-06	7.88e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—EGFR—ovarian cancer	2.17e-06	7.88e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—AKT1—ovarian cancer	2.16e-06	7.84e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	2.16e-06	7.83e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.16e-06	7.82e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TP53—ovarian cancer	2.15e-06	7.8e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	2.15e-06	7.79e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MYC—ovarian cancer	2.14e-06	7.76e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	2.14e-06	7.76e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	2.14e-06	7.75e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—EGFR—ovarian cancer	2.14e-06	7.75e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	2.14e-06	7.75e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	2.13e-06	7.74e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MAPK1—ovarian cancer	2.13e-06	7.73e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—EGFR—ovarian cancer	2.13e-06	7.73e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	2.09e-06	7.59e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	2.09e-06	7.59e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—AKT1—ovarian cancer	2.09e-06	7.58e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	2.08e-06	7.53e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TP53—ovarian cancer	2.08e-06	7.53e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TP53—ovarian cancer	2.07e-06	7.49e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	2.06e-06	7.46e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—KRAS—ovarian cancer	2.05e-06	7.44e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	2.05e-06	7.41e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	2.04e-06	7.41e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—AKT1—ovarian cancer	2.04e-06	7.4e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—AKT1—ovarian cancer	2.03e-06	7.36e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CAV1—ovarian cancer	2.02e-06	7.33e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—KRAS—ovarian cancer	2.02e-06	7.32e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PIK3CA—ovarian cancer	2.02e-06	7.32e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—KRAS—ovarian cancer	2.02e-06	7.31e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—AKT1—ovarian cancer	2.01e-06	7.3e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TP53—ovarian cancer	2.01e-06	7.29e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1.99e-06	7.21e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—HRAS—ovarian cancer	1.99e-06	7.2e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTEN—ovarian cancer	1.98e-06	7.17e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TP53—ovarian cancer	1.98e-06	7.17e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	1.98e-06	7.17e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.98e-06	7.17e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IL6—ovarian cancer	1.97e-06	7.14e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	1.95e-06	7.05e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	1.94e-06	7.05e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	1.92e-06	6.97e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IL6—ovarian cancer	1.9e-06	6.89e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	1.89e-06	6.86e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IL6—ovarian cancer	1.89e-06	6.86e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	1.89e-06	6.84e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTEN—ovarian cancer	1.86e-06	6.76e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	1.86e-06	6.73e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	1.85e-06	6.71e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.85e-06	6.71e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.84e-06	6.67e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IL6—ovarian cancer	1.84e-06	6.67e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	1.84e-06	6.66e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TP53—ovarian cancer	1.82e-06	6.61e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	1.82e-06	6.59e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	1.82e-06	6.59e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IL6—ovarian cancer	1.81e-06	6.57e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TP53—ovarian cancer	1.79e-06	6.51e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TP53—ovarian cancer	1.79e-06	6.49e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TP53—ovarian cancer	1.76e-06	6.37e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—AKT1—ovarian cancer	1.75e-06	6.36e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—AKT1—ovarian cancer	1.75e-06	6.33e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—HRAS—ovarian cancer	1.74e-06	6.32e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—HRAS—ovarian cancer	1.72e-06	6.22e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—HRAS—ovarian cancer	1.71e-06	6.21e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	1.7e-06	6.15e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	1.69e-06	6.12e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	1.68e-06	6.09e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	1.67e-06	6.06e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL6—ovarian cancer	1.67e-06	6.05e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—AKT1—ovarian cancer	1.65e-06	5.98e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL6—ovarian cancer	1.64e-06	5.96e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL6—ovarian cancer	1.64e-06	5.94e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TP53—ovarian cancer	1.63e-06	5.92e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.62e-06	5.87e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL6—ovarian cancer	1.61e-06	5.83e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	1.56e-06	5.66e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—AKT1—ovarian cancer	1.54e-06	5.58e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—AKT1—ovarian cancer	1.52e-06	5.49e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—AKT1—ovarian cancer	1.51e-06	5.48e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—AKT1—ovarian cancer	1.51e-06	5.48e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL6—ovarian cancer	1.49e-06	5.42e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	1.48e-06	5.38e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.41e-06	5.11e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.4e-06	5.06e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	1.38e-06	5e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.32e-06	4.77e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTEN—ovarian cancer	1.22e-06	4.42e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—AKT1—ovarian cancer	1.14e-06	4.13e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—AKT1—ovarian cancer	1.07e-06	3.9e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	8.6e-07	3.12e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—AKT1—ovarian cancer	7.03e-07	2.55e-05	CbGpPWpGaD
